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Abstract
Background—Generalized Anxiety Disorder (GAD) is highly comorbid with depression.
Depression is associated with elevated levels of the inflammation marker C-reactive protein
(CRP), cross-sectionally and over time. To date, no studies have looked at the association of CRP
with GAD.
Methods—Ten waves of data from the prospective population-based Great Smoky Mountains
Study (N = 1,420) were used, covering children in the community aged 9-16, 19, and 21 years old.
Structured interviews were used at each assessment to assess GAD symptoms, diagnosis, and
cumulative episodes. Bloodspots were collected and assayed for CRP levels.
Results—GAD was associated with increased levels of CRP in bivariate cross-sectional
analyses. These bivariate associations, however, were attenuated after accounting for
demographic, substance use, and health-related covariates. In longitudinal models, there was little
evidence that CRP predicted later GAD. Associations from GAD to later CRP were attenuated in
models adjusted for health-related coavariates and there was evidence that the GAD-CRP
association was mediated by BMI and medication use.
Conclusions—Similar to depression, GAD was associated with elevated levels of CRP, but the
effect of GAD on CRP levels was explained by the effect of GAD on health-related behaviors
such as BMI and medication use. This study suggests differences in the association between
inflammation and depression and GAD.
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Introduction
Generalized anxiety disorder (GAD) is characterized by excessive or uncontrollable anxiety
and worry, is associated with a range of physical symptoms (American Psychiatric
Association, 1994), and is highly comorbid with depression at every stage of life (Angold et
al., 1999a, Kessler et al., 2005) (Moffitt et al., 2007b). Several lines of empirical research
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have established that GAD and depression share many, although not all psychosocial and
biological risk factors and correlates (American Psychiatric Association, 1994). Depression
is associated with elevated levels of pro-inflammatory cytokines and the proteins released in
response to increasing cytokine levels. The acute phase protein C-reactive protein (CRP) has
been the focus of extensive epidemiologic investigation because of the association of
elevated plasma CRP levels (>3 mg/L) with cardiovascular risk (The Emerging Risk Factors
Collaboration, 2010, Shah et al., 2009) and aspects of metabolic syndrome (Tamakoshi et
al., 2003, Pradhan et al., 2002, Ridker et al., 2003). Recent work on depression has
identified robust cross-sectional and longitudinal associations with CRP (Howren et al.,
2009, Copeland et al., 2012). Are such associations also observable between GAD and
CRP?
Several previous findings suggest that such an association should be identified. First, family
and twin studies have documented co-transmission of depression and GAD (Kendler et al.,
1995, Eley and Stevenson, 1999, Thapar and McGuffin, 1997, Middeldorp et al., 2005) as
well as strong bivariate genetic correlations between depression and GAD (Kendler et al.,
2007, Kendler, 1996). Second, hypothalamic-pituitary adrenal axis and autonomic nervous
system activity have both been implicated in depressive symptoms and CRP production (for
reviews (Raison et al., 2006, Dantzer et al., 2008)); these systems are generally also
activated in the context of anxiety (O’Donovan et al., 2010, Toker et al., 2005, Pitsavos et
al., 2006), although few studies of physiological correlates have specifically focused on
GAD. Third, depression and GAD tend to be responsive to the same active ingredients in
drugs (Kuzma and Black, 2004). Finally, a number of studies comparing psychosocial
correlates of depression and GAD have identified at least some similarities (Moffitt et al.,
2007a).
Recent work has, however, also identified differences between depression and GAD,
suggesting at least partially different etiological pathways. For example, divergence in
correlates was found for a number of psychosocial adversities (Moffitt, 2007, Shanahan,
2008) and temperamental traits (Moffitt, 2007). Furthermore, a family history of depression
was specifically associated with depression, but not with GAD (Moffitt, 2007; Shanahan,
2008), suggesting potential differences in at least some of the biological bases of these
disorders.
The goal of this study was to test whether GAD would be associated with increased levels of
the systemic inflammation marker CRP, both cross-sectionally and over time. It is also
plausible, as was observed in part with depression (Copeland et al., 2012), that a portion of
any identified association is accounted for by other health-related variables such as body-
mass index, medication use, and smoking. Such an association would provide additional
evidence for biological overlap between depression and GAD and provide some support for
the combination of these disorders in DSM-5. A lack of association between GAD and CRP
would implicate distinct biological processes in these otherwise closely-linked disorders.
Methods and Materials
Participants
The Great Smoky Mountains Study is a longitudinal study of the development of psychiatric
disorder and need for mental health services in rural and urban youth (Costello et al., 1996,
Costello et al., 2003). A representative sample of three cohorts of children, age 9, 11, and 13
at intake, was recruited from 11 counties in western North Carolina using a multi-stage
selection process. All children scoring above a predetermined cut-point (the top 25% of the
total scores) on a screening questionnaire, plus a 1-in-10 random sample of the rest, were
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recruited for detailed interviews. Of all subjects recruited, 80% (N=1420) agreed to
participate.
Subjects were assessed annually to age 16 then again at ages 19 and 21. Participants were
interviewed as closely as possible to their birthday each year. Across all waves, participation
rates averaged 84% (range: 74-94%). About 8% of the area residents and the sample are
African American, less than 1% are Hispanic, and 3% are American Indian.
Procedures
The parent (biological mother for 83% of interviews) and subject were interviewed by
trained interviewers separately until the subject was 16, and subjects only thereafter. Before
the interviews began, parent and child signed informed consent forms approved by the Duke
University Medical Center Institutional Review Board. Each parent and child received an
honorarium for their participation.
Using a previously described procedure (Worthman and Stallings, 1997), blood samples
were obtained at the beginning of each in-person assessment, as follows: two finger-prick
samples (yielding 10 spots total per visit) were collected at a 20-minute intervals, applied to
standardized collection paper, immediately refrigerated upon drying, and express shipped
(without refrigeration) to the laboratory within two weeks of collection. Samples were then
stored at −28°C until they were assayed. This protocol is consistent with the rigorous quality
control program developed for newborn screening programs (Mei et al., 2001) and has been
used in a number of epidemiologic studies involving blood spot CRP measures (McDade et
al., 2006, Williams and McDade, 2009).
Assessment
Generalized Anxiety is characterized by excessive anxiety and worry that a person finds
difficult to control, and is associated with a range of physical symptoms (restlessness, easily
fatigues, difficulty concentrating, irritability, muscle tension, and sleep disturbance)
(American Psychiatric Association, 1994). Generalized anxiety disorder variables were
assessed using the Child and Adolescent Psychiatric Assessment until age 16, and its
upward extension, the Young Adult Psychiatric Assessment thereafter (Angold and Costello,
2000, Angold et al., 1999b). These structured interviews were coded by a trained interviewer
and each interview was then checked by a supervisor. The time frame for determining the
presence of most behaviors was the past three months to minimize forgetting and recall
biases, although onset dates were also collected for all symptoms. A symptom was counted
as present if reported by either parent or child or both, as is standard in clinical practice.
Scoring programs written in SAS by the senior authors combined information about the date
of onset, duration, and intensity of each symptom to create GAD diagnoses according to the
fourth edition of the Diagnostic and Statistical Manual of the American Psychiatric
Association (American Psychiatric Association, 1994). Two-week test-retest reliability of
diagnoses is comparable to that of other highly-structured child psychiatric interviews
(Angold and Costello, 1995). Construct validity as judged by 10 different criteria including
comparison to other interviews and ability to predict mental health service use is good to
excellent (Angold and Costello, 2000). Generalized anxiety disorder status was measured by
two variables: Current generalized anxiety disorder (binary) and the number of total
generalized anxiety symptoms (range: 0-6). Cumulative generalized anxiety exposure was
assessed by looking at the total number of GAD episodes reported up until the current
assessment (range: 0-3). This variable was included because of the evidence that cumulative
depressive episodes predicted later CRP levels and other studies linking perturbations in
inflammation levels to repeated psychological distress (Danese et al., 2008, Copeland et al.,
2012).
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C-Reactive Protein—Our assay for CRP in whole-blood spots was a biotin-Streptavidin
based immunofluorometric system improving on a previously published method (McDade et
al., 2004). One assay was completed for each subject at each observation. Streptavidin A-
coated microtiter plates bind a biotinylated capture antibody to CRP, clone C2. A second
Europium-labeled antibody then binds to the Streptavidin A Biotin-C2-CRP complex;
fluorescence of the resultant complex is directly proportional to the CRP concentration in
each well. Minimum detectable dose for the assay is .010 mg/L. For low, medium, high, and
very high controls (.022, .259, 1.208, and 3.271 mg/L, respectively), within-assay
coefficient of variation (CV)(precision) is 2.0%, 1.2%, 1.6%, and 1.4%, respectively, while
between-assay CV (reliability) runs 14.4%, 13.9%, 12.3% and 10.9%, respectively. CRP
remains stable in dried blood spots for at least 5 days at room temperature or 14 days at 4
°C, and stable for years at −26 °C.
A validation study was performed with matched serum and blood spot samples assayed for
CRP (n=38). As has been reported for many other analytes including CRP (Worthman and
Stallings, 1997, McDade et al., 1997, McDade et al., 2004), a close linear correlation was
identified between serum and blood spot CRP values (n=29; R2 = .98, p<.0001). Serum
equivalents therefore were calculated using the following algorithm based on the serum-
blood spot regression: serum (hsCRP) = 1.38*(Blood Spot CRP Value) – 0.97. Blood spot
CRP measures have been used in a number of epidemiologic studies (Williams and
McDade, 2009, McDade et al., 2006, McDade et al., 2005). Observations with values above
10 mg/L indicate frank infection and were removed from statistical analysis (N=190 from a
total of 6000 observations), whereas values below 10 mg/L the extent of chronic low grade
systemic inflammation associated with cardiovascular and metabolic risk (Pearson et al.,
2003).
Covariates included variables typically associated with variation in CRP levels (Woodward
et al., 2003, Elovainio et al., 2006) or used as covariates in studies of CRP and depression
(Gimeno et al., 2009, Stewart et al., 2009, Janicki Deverts et al., 2010, Matthews et al.,
2010). These included age, sex, race, BMI, medication use, substance use, low SES, and
recent physical ailments. BMI was calculated from weight and height measurements
completed at each assessment. For all assessments completed before subjects were 20, BMI
values were corrected for age and sex (Ogden et al., 2002). The substance use assessment of
the CAPA and YAPA interviews assesses current nicotine, alcohol, and illicit drug use.
Dichotomous variables were included to indicate recent use of these substances. A physical
health problems survey adapted from Form HIS-1A (1998), US Department of Commerce
for the U.S. Public Health Service was administered to assess 39 common ailments (e.g.,
diabetes, anemia, mononucleosis). A binary variable indicating any health ailments within
the last 12 months was used for all analyses. Analyses were also tested using the following
separate health categories: atopic (e.g., food/digestive allergy, asthma, and, respiratory
allergy), injuries, infections (tonsilitis, ear infection, frequent diarrhea or colitis, and urinary
tract infections) and chronic diseases (e.g., diabetes, epilepsy, cancer and chronic heart
disease). Medication use within the prior year was also assessed from the Child and
Adolescent Services Assessment (Ascher et al., 1996), which focuses on psychotropic
medications, but also assessed prescribed medications not related to psychiatric problems.
All analyses were tested using a broad-based medication use variables as well as categories
for individual medication groups (e.g., antidepressant, stimulant, and other prescribed
medications). Low SES coded whether the subject’s family displayed any 2 of the following
3 indicators: income below the federal poverty line, low parental education attainment, and
low parental occupation status. Additional physiological covariates evaluated alongside CRP
in older samples at risk for cardiovascular problems (e.g., blood pressure, lipids, or insulin)
were not assessed.
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All subjects were assigned a weight inversely proportional to their probability of selection,
so that the results are representative of the population from which the sample was drawn and
not biased from the oversampling procedure. CRP values were positively skewed and were
log10-transformed after scaling for non-negative values by adding 1. Models predicting
GAD symptoms or cumulative GAD episodes employed Poisson regression, models
predicting diagnostic status employed logistic regression and those predicting CRP
employed linear regression. All associations were tested using weighted regression models
in a generalized estimating equations framework implemented by SAS PROC GENMOD.
For all analyses, multiple observations were used for each subject and robust variance
(sandwich type) estimates adjusted the standard errors of the parameter estimates for the
repeated observations. The covariance matrix was specified as autoregressive in all analyses.
All longitudinal models used values from the prior assessment to predict current levels of
the outcome variable. As such, only subjects with multiple assessments were included and
subjects with more than two assessments contributed multiple observations. For example, if
a subject had 5 assessments, then they contributed 4 observations to the current analyses
(wave 1 predicting wave 2, wave 2 predicting wave 3, wave 3 predicting wave 4, and wave
4 predicting wave 5).
Missing data
By age 21, 8806 total assessments had been completed. Of these, bloodspots were obtained
for 6087 (69.1%). Bloodspots were not available either because the subject refused or
because the interviews were completed by phone. For in-person interviews, 79.4% of
subjects agreed to provide bloodspots. Comparisons of observations in which blood spots
were collected to those in which the subjects refused indicated no significant differences on
any of the GAD outcomes. Of the 6087 bloodspots collected, 6000 (98.6%) were
successfully assayed for CRP (190 were removed due to elevated CRP levels indicating
infection). Of the 1420 study participants, 1,334 (93.9%) provided blood spot samples
assayed for CRP in one year or more. The median number of CRP samples provided was 5
(mean =4.77 (SD=2.24); range =1-9).
Results
Sample characteristics
Table 1 shows the characteristics of the full analytic sample in person-observations (5810
observations of 1334 subjects). GAD-related outcomes were significantly associated with
sex, age, BMI, tobacco use, alcohol use, illicit drug use, medication use, and current health
ailments. CRP was associated with age, BMI, tobacco use, alcohol use, other drug use,
medication use, current health ailments and low SES. This pattern of findings suggests that
all covariates merit inclusion.
The overlap between GAD and depression variables was high. Thirty-nine-point-nine
percent of those meeting criteria for GAD also met criteria for a depressive disorder
(OR=40.9; 95%CI =18.0-92.9, p <0.0001). There was similarly high overlap between
symptoms (r = 0.72, p < 0.0001) and cumulative episodes to date (r = 0.55, p < 0.0001). If
CRP is associated with GAD, it is reasonable to ask if such associations are independent of
depression.
Cross-sectional Associations
A series of regression models tested the cross-sectional associations between CRP and all
GAD-related outcomes (table 2). For each outcome, a simple bivariate model was tested as
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well as a model adjusting for covariates. There was strong evidence of association between
CRP and GAD-related outcomes in bivariate models. All associations were attenuated to
nonsignificance by the inclusion of health-related covariates. BMI and medication use were
significant predictors in all models predicting CRP.
Longitudinal Associations
Longitudinal bi-directional associations were tested in a series of similar models similar to
those for the cross-sectional associations (table 3). The simple longitudinal model predicted
the outcome using the predictor and prior status on the outcome variable (e.g., prior CRP
and GAD symptoms predicting current GAD symptoms). As such, this model predicts
change in the outcome variable across assessments. There was little evidence of either CRP
predicting later GAD-related outcomes or vice versa in the simple models. The lone
exception was GAD symptoms predicting later CRP levels adjusting for prior CRP. This
association, like other marginal associations, was attenuated after accounting for current
health-related covariates. The models testing effects of GAD-related variables on later CRP
levels implicated a common set of covariates which included race, time since the last
interview, BMI, nicotine use, and current medication use.
These concurrent covariates may mediate or account for the association between past GAD
symptoms and current CRP as has been observed, in part, for depression (Copeland et al.,
2012). Each significant covariate was tested as a potential mediator using a multistage
regression approach (Baron and Kenny, 1986, MacKinnon et al., 2002). Identification of
potential mediators required the following: 1) GAD symptoms were associated with the
covariate (table 4, column 1); 2) In models controlling for the GAD symptoms, the covariate
was associated with CRP (column 2); 3) In models controlling for the covariate, the
association between the GAD symptoms and CRP was either no longer statistically
significant or was attenuated (column 3); and 4) A statistically significant indirect path
existed between the GAD symptoms and CRP through the covariate, as measured by the
Sobel test (Sobel, 1982) (column 4). Neither race nor time since last interview were
associated with the GAD symptoms and, thus, were not included in table 3. Both BMI and
medication mediated the association from prior GAD symptoms to current CRP.
Followup analyses
CRP levels greater than > 3 mg/L indicate increased risk for cardiovascular disease in adults
(Pearson et al., 2003). There was no evidence that changes to the definition of CRP, either
by dichotomizing CRP levels at CRP > 3 mg/L or by including cases with CRP > 10 mg/L
(which is indicative of acute infection) affected the results of either the cross-sectional or
longitudinal analysis. It is plausible that the association of CRP with GAD differs is found in
some subgroups but not in others. To test for this pattern, interaction terms were entered into
each of the simple/bivariate between the predictor and each demographic variable (sex and
race) or significant covariate. Significant interactions occurred at the rate expected by
chance and were no more likely to include one demographic variable or covariate than
another. Finally, it is possible - albeit unlikely - that it is the portion of GAD that is
independent of depression that is associated with CRP levels. All analyses were rerun
including depression variables as covariates. As expected, this did not change the pattern of
associations.
Discussion
GAD is highly comorbid with depression (Moffitt et al., 2007b), and depression is both
directly and indirectly associated with elevated levels of CRP (Howren et al., 2009). On this
basis, we predicted that GAD would also be associated with elevated levels of CRP. There
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was evidence supporting this hypothesis in bivariate associations both cross-sectionally and
over time. These associations attenuated, however, with the inclusion of health-related
covariates and both BMI and medication use which mediated the longitudinal associations
between GAD variables and later CRP levels. Thus, GAD does affect levels of CRP, but this
effect is accounted for by the effect GAD on health-related behaviors. The direct association
with elevated low-grade inflammation is an area of divergence between GAD and
depression for the age-groups examined here.
Despite the extensive literature on the depression-CRP link, only few studies have looked at
the association between CRP and any measure of anxiety. The ATTICA study examined
concurrent associations between State-Trait Anxiety Inventory scores and a number of
markers of immunity/inflammation including hsCRP in a sample of 853 adults (Pitsavos et
al., 2006). They found a small, but significant, association (rho=0.18) that persisted after
controlling for relevant covariates. A case-control study of 27 anxious patients and 29
nonanxious controls found no association between CRP levels and anxiety as measured by a
self-report questionnaire (O’Donovan et al., 2010). Finally, a test of the CRP-anxiety
association in a large sample of employees completing a routine health exam at an Israeli
medical center found no association (Toker et al., 2005). These studies suggest a consensus
for little evidence of association between CRP with anxiety. In our study which employed
structured interviews to assess GAD, the aspect of anxiety most closely tied to depression,
there was no independent association.
If indeed depression, but not GAD, is associated with CRP directly, what does this
specificity suggest? Although the areas of overlap between GAD and depression are legion
(Moffitt et al., 2007b, Watson, 2005), divergence in biological correlates may reinforce the
notion that these disorders have at least partially distinct neurobiological profiles. There is
also evidence that GAD and depression are preceded by somewhat different profiles of
psychosocial risk factors (Moffitt et al., 2007a). The study of biological correlates has
generally been limited to markers of HPA axis function. Here again, results have been
mixed with some studies showing increased levels of basal and peak salivary cortisol levels
(Mantella et al., 2008) and other studies failing to find any association of GAD with diurnal
cortisol levels (Hoehn-Saric et al., 1991). Similar mixed results have been reported
regarding nonsuppresssion of cortisol in response to the dexamethasone suppression test
(Schweizer et al., 1986, Tiller et al., 1988). Studies of HPA-related indicators and
depression, however, have been plagued by similar inconsistencies (Kaufman et al., 2001).
One general conclusion from the literature is that disorder-biological correlate associations
still tend to be small, affected by a range of health-related behaviors, and often limited to
specific subgroups (by age, number of disorder episodes). Thus, while our findings are
consistent with a conceptualization of GAD and depression as closely-linked entities with
distinct biological correlates, more work needs to be done on the conditions under which
such associations are detectable for all psychiatric disorders.
Bivariate associations between GAD and CRP seem to be attenuated by a broad set of
health-related variables including substance use, body-mass index, medication use. A similar
set of variables attenuated the associations of depression-related variables on later CRP
levels (albeit not to the point of nonsignificance for cumulative depressive episodes).
Analyses testing bivariate associations ignore the normative clustering of these multiple
health-risk behaviors and the elevated levels of CRP. Although the influence of any single
risk factor may be important in terms of understanding the pathophysiology of mild
inflammation, these risk factors are much difficult to tease apart in the real world. Risk
reduction strategies may opt to use this normative clustering to identify subjects at highest
risk for elevated inflammation patterns rather than focusing on individual risk factors.
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The Great Smoky Mountains study has several strengths besides its longitudinal, prospective
design: A population-based design that minimized selection biases; anxiety variables
assessed repeatedly with structured interviews that allowed us to look at various aspects of
anxiety; repeated collection of bloodspots that allowed for subjects to provide up to 9 values
of CRP across 12 years; and assessment of a wide range of domains that allowed us to
control for covariates of anxiety and CRP. But the sample is not representative of the U.S.
population (Native Americans overrepresented and African Americans and Latinos under-
represented).
The criteria for GAD may change in DSM-5. The primary proposed changes for DSM-5
GAD include removing criterion B (difficulty controlling worry), reducing the threshold for
criterion C (associated symptoms), and adding a behavioral avoidance criterion (DSM-5
Anxiety Disorders Work Group, 2010). The first change is only meant to remove a
redundancy and the reduced threshold for criterion C already applies in children (Andrews et
al., 2010). The primary change then, as it relates to the current study, is the additional of the
behavioral avoidance criterion. One goal of this addition is indeed to increase differentiation
with other anxiety and mood disorders (Andrews et al., 2010). While this new criterion is
only propositional, this change, if adopted, may affect the association of GAD with CRP.
Conclusion
Our study provides little support for a robust association between GAD and CRP. Instead,
significant cross-sectional or longitudinal associations were entirely attenuated by a cluster
of health-related covariates known to predict both CRP and anxiety. In the case of
depression, there is evidence for an independent effect of recurrent depressive episodes on
later CRP levels (Copeland et al., 2012), but this was not the case for GAD. This suggests
caution in interpretation of the recent evidence of overlap between GAD and depression in
developmental course and lifetime comorbidity. Despite general similarities, it has not been
demonstrated that depression and GAD share biological correlates related either to HPA-
axis function or CRP levels. These differences may prove instructive in understanding the
specificity of associations between negative emotions and inflammation.
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Table 4
Tests of potential mediators of the association between GAD symptoms and later CRP
1. GAD symptoms to
mediator
2. Mediator to CRP 3. GAD symptoms to
CRP
4. Sobel test
B (SE) B (SE) B (SE) p
BMI 0.54 (0.18), p<0.01 0.01 (0.001), p<0.001 0.02 (0.009), p=0.07 <0.01
Nicotine Use 0.26 (0.07), p<0.001 0.04 (0.02), p<0.05 0.02 (0.009), p<0.05 0.08
Medication Use 0.25 (0.06) , p<0.001 0.04 (0.01), p<0.001 0.02 (0.009), p<0.05 <0.01
Models were tested with either Poissona or logisticb regression. Columns numbered 2 and 3 provide results from models in which both GAD
symptoms variable and potential mediator predicted current CRP status. Models adjusted for demographic covariates and prior CRP status. Sobel
test assess significance of indirect pathway. CRP=C-Reactive Protein; BMI = Body-mass index. Sx = symptoms.
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